JP2015513901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513901A5 JP2015513901A5 JP2015503230A JP2015503230A JP2015513901A5 JP 2015513901 A5 JP2015513901 A5 JP 2015513901A5 JP 2015503230 A JP2015503230 A JP 2015503230A JP 2015503230 A JP2015503230 A JP 2015503230A JP 2015513901 A5 JP2015513901 A5 JP 2015513901A5
- Authority
- JP
- Japan
- Prior art keywords
- raf
- cancer
- polypeptide
- inhibitor
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616999P | 2012-03-28 | 2012-03-28 | |
| US61/616,999 | 2012-03-28 | ||
| US201261708372P | 2012-10-01 | 2012-10-01 | |
| US61/708,372 | 2012-10-01 | ||
| PCT/US2013/029513 WO2013148100A1 (en) | 2012-03-28 | 2013-03-07 | C-raf mutants that confer resistance to raf inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018048824A Division JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513901A JP2015513901A (ja) | 2015-05-18 |
| JP2015513901A5 true JP2015513901A5 (https=) | 2016-04-21 |
| JP6348898B2 JP6348898B2 (ja) | 2018-06-27 |
Family
ID=47892065
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503230A Active JP6348898B2 (ja) | 2012-03-28 | 2013-03-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2018048824A Active JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2020019636A Pending JP2020103291A (ja) | 2012-03-28 | 2020-02-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018048824A Active JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2020019636A Pending JP2020103291A (ja) | 2012-03-28 | 2020-02-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9629839B2 (https=) |
| EP (3) | EP2831589B1 (https=) |
| JP (3) | JP6348898B2 (https=) |
| KR (1) | KR20140139510A (https=) |
| CN (1) | CN104204806B (https=) |
| AU (1) | AU2013240483B2 (https=) |
| BR (1) | BR112014023496A2 (https=) |
| CA (1) | CA2864169A1 (https=) |
| EA (1) | EA028135B1 (https=) |
| ES (3) | ES2908078T3 (https=) |
| MX (1) | MX351945B (https=) |
| PL (1) | PL2831589T3 (https=) |
| PT (1) | PT2831589T (https=) |
| TR (1) | TR201808010T4 (https=) |
| WO (1) | WO2013148100A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2831589B1 (en) * | 2012-03-28 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | C-raf mutants that confer resistance to raf inhibitors |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| KR102537840B1 (ko) | 2018-07-13 | 2023-05-31 | 삼성전자 주식회사 | 서버 장치 및 다른 장치들의 위치 정보를 수집하는 방법 |
| WO2020163771A1 (en) * | 2019-02-08 | 2020-08-13 | Portage Glasgow Limited | Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides |
| WO2021225980A1 (en) * | 2020-05-04 | 2021-11-11 | Dna-Seq, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618670A (en) * | 1988-08-26 | 1997-04-08 | The United States Of America As Represented By The Department Of Health & Human Services | Detection method for c-raf-1 genes |
| WO2005009367A2 (en) | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| CA2533803A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| CN101516376A (zh) * | 2006-09-18 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 用于治疗携带egfr突变的癌症的方法 |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| EP2102362B1 (en) * | 2006-11-16 | 2012-07-04 | Mount Sinai School of Medicine of New York University | Compositions and methods for detecting noonan syndrome |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| CN103038364A (zh) * | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| EP2831589B1 (en) * | 2012-03-28 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | C-raf mutants that confer resistance to raf inhibitors |
-
2013
- 2013-03-07 EP EP13710263.8A patent/EP2831589B1/en active Active
- 2013-03-07 BR BR112014023496A patent/BR112014023496A2/pt not_active IP Right Cessation
- 2013-03-07 ES ES20159381T patent/ES2908078T3/es active Active
- 2013-03-07 JP JP2015503230A patent/JP6348898B2/ja active Active
- 2013-03-07 WO PCT/US2013/029513 patent/WO2013148100A1/en not_active Ceased
- 2013-03-07 KR KR1020147026716A patent/KR20140139510A/ko not_active Ceased
- 2013-03-07 US US14/387,735 patent/US9629839B2/en active Active
- 2013-03-07 ES ES18153021T patent/ES2790896T3/es active Active
- 2013-03-07 ES ES13710263.8T patent/ES2673070T3/es active Active
- 2013-03-07 PL PL13710263T patent/PL2831589T3/pl unknown
- 2013-03-07 EA EA201491780A patent/EA028135B1/ru not_active IP Right Cessation
- 2013-03-07 EP EP20159381.1A patent/EP3693741B1/en active Active
- 2013-03-07 PT PT137102638T patent/PT2831589T/pt unknown
- 2013-03-07 CN CN201380014747.6A patent/CN104204806B/zh active Active
- 2013-03-07 EP EP18153021.3A patent/EP3333575B1/en active Active
- 2013-03-07 MX MX2014011686A patent/MX351945B/es active IP Right Grant
- 2013-03-07 TR TR2018/08010T patent/TR201808010T4/tr unknown
- 2013-03-07 AU AU2013240483A patent/AU2013240483B2/en not_active Ceased
- 2013-03-07 CA CA2864169A patent/CA2864169A1/en not_active Abandoned
-
2017
- 2017-03-29 US US15/472,934 patent/US20170204383A1/en not_active Abandoned
-
2018
- 2018-03-16 JP JP2018048824A patent/JP6661685B2/ja active Active
-
2019
- 2019-01-23 US US16/255,251 patent/US20190142830A1/en not_active Abandoned
-
2020
- 2020-02-07 JP JP2020019636A patent/JP2020103291A/ja active Pending
-
2021
- 2021-08-11 US US17/399,563 patent/US11788151B2/en active Active
-
2023
- 2023-09-11 US US18/464,360 patent/US12146196B2/en active Active
-
2024
- 2024-10-14 US US18/914,634 patent/US20250034652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma | |
| Ferone et al. | Cells of origin of lung cancers: lessons from mouse studies | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| JP2015513901A5 (https=) | ||
| US20250276066A1 (en) | Methods, compositions and compounds for treating age-related diseases and conditions | |
| Okayama et al. | NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression | |
| Rubino et al. | Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer | |
| PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
| JP2005506971A5 (https=) | ||
| JP2015530080A5 (https=) | ||
| EA201201640A1 (ru) | Способы определения устойчивости рака к ингибиторам гистондеацетилазы | |
| JP2017516458A5 (https=) | ||
| Cucurull et al. | Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: the immune regulatory role of KRAS and novel therapeutic strategies | |
| JP2016513456A5 (https=) | ||
| Kato et al. | Lactate dehydrogenase and hemolysis in sickle cell disease | |
| Draenert et al. | The prevalence of tooth hypersensitivity following periodontal therapy with special reference to root scaling. A systematic review of the literature. | |
| JP2019512020A5 (https=) | ||
| ES2813877T3 (es) | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos | |
| Mangana et al. | Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland | |
| JP2014533960A5 (https=) | ||
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| JP2014531020A5 (https=) | ||
| Algazi et al. | Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma | |
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target |